New drug combo aims to keep lung cancer in check after initial treatment
NCT ID NCT07545954
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests whether adding an experimental drug (DSP-0390) to the immunotherapy atezolizumab can safely help prevent extensive stage small cell lung cancer from growing back after initial chemotherapy and immunotherapy. About 20 adults whose cancer did not worsen after first-line treatment will receive the combination as maintenance therapy. The main goal is to check safety and tolerability, with a secondary look at how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DSP-0390 (a cholesterol synthesis inhibitor) and atezolizumab (an immunotherapy drug)
What this could lead to
If this combination is safe and shows promise, it could lead to a new maintenance treatment option to help keep extensive stage small cell lung cancer from progressing after initial therapy.
What could go wrong
This is a very early, small pilot study with only 20 participants. The combination may cause side effects or not work better than current standard care. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact